183 related articles for article (PubMed ID: 17468949)
1. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients.
Chang JC; Makris A; Gutierrez MC; Hilsenbeck SG; Hackett JR; Jeong J; Liu ML; Baker J; Clark-Langone K; Baehner FL; Sexton K; Mohsin S; Gray T; Alvarez L; Chamness GC; Osborne CK; Shak S
Breast Cancer Res Treat; 2008 Mar; 108(2):233-40. PubMed ID: 17468949
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of using tissue microarray cores of paraffin-embedded breast cancer tissue for measurement of gene expression: a proof-of-concept study.
Drury S; Salter J; Baehner FL; Shak S; Dowsett M
J Clin Pathol; 2010 Jun; 63(6):513-7. PubMed ID: 20498025
[TBL] [Abstract][Full Text] [Related]
5. Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue.
Hartmann K; Schlombs K; Laible M; Gürtler C; Schmidt M; Sahin U; Lehr HA
Diagn Pathol; 2018 Oct; 13(1):83. PubMed ID: 30342538
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
7. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
[TBL] [Abstract][Full Text] [Related]
8. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling.
Zembutsu H; Suzuki Y; Sasaki A; Tsunoda T; Okazaki M; Yoshimoto M; Hasegawa T; Hirata K; Nakamura Y
Int J Oncol; 2009 Feb; 34(2):361-70. PubMed ID: 19148470
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
Layman RM; Thomas DG; Griffith KA; Smerage JB; Helvie MA; Roubidoux MA; Diehl KM; Newman LA; Sabel MS; Hayman JA; Pierce LJ; Hayes DF; Schott AF
Clin Cancer Res; 2007 Jul; 13(14):4092-7. PubMed ID: 17634534
[TBL] [Abstract][Full Text] [Related]
10. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
[TBL] [Abstract][Full Text] [Related]
11. Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samples.
Pu T; Guo P; Qiu Y; Chen S; Yang L; Sun L; Ye F; Bu H
Int J Clin Exp Pathol; 2015; 8(9):10565-74. PubMed ID: 26617766
[TBL] [Abstract][Full Text] [Related]
12. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
13. Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection.
Tramm T; Hennig G; Kyndi M; Alsner J; Sørensen FB; Myhre S; Sørlie T; Overgaard J
Virchows Arch; 2013 Dec; 463(6):775-86. PubMed ID: 24100522
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Chang JC; Wooten EC; Tsimelzon A; Hilsenbeck SG; Gutierrez MC; Elledge R; Mohsin S; Osborne CK; Chamness GC; Allred DC; O'Connell P
Lancet; 2003 Aug; 362(9381):362-9. PubMed ID: 12907009
[TBL] [Abstract][Full Text] [Related]
15. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Gianni L; Zambetti M; Clark K; Baker J; Cronin M; Wu J; Mariani G; Rodriguez J; Carcangiu M; Watson D; Valagussa P; Rouzier R; Symmans WF; Ross JS; Hortobagyi GN; Pusztai L; Shak S
J Clin Oncol; 2005 Oct; 23(29):7265-77. PubMed ID: 16145055
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens.
Sadi AM; Wang DY; Youngson BJ; Miller N; Boerner S; Done SJ; Leong WL
BMC Cancer; 2011 Jun; 11():253:1-13. PubMed ID: 21679412
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
19. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide gene expression profiling of formalin-fixed paraffin-embedded breast cancer core biopsies using microarrays.
Budczies J; Weichert W; Noske A; Müller BM; Weller C; Wittenberger T; Hofmann HP; Dietel M; Denkert C; Gekeler V
J Histochem Cytochem; 2011 Feb; 59(2):146-57. PubMed ID: 21339180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
